Philips Healthcare unveiled two MR scanners on the RSNA 2008 exhibit floor: one at 3T, the other at 1.5T. Both emphasize productivity and clinical value, albeit by different means.
Philips Healthcare unveiled two MR scanners on the RSNA 2008 exhibit floor: one at 3T, the other at 1.5T. Both emphasize productivity and clinical value, albeit by different means.
The Achieva 3.0T TX expands the range of 3T applications possible with routine scanning through higher speed and better image quality using a novel technology dubbed MultiTransmit RF management. This technology automatically adjusts the RF signal to the specific body habitus and anatomy of the patient being scanned. The results, according to Philips, are higher acquisition speed, as well as better image quality and consistency. Together they offer new clinical possibilities for scanning the breast, liver, pelvis, and spine at 3T, according to the company.
Philips extended its current 1.5T platform with the Achieva SE, a scanner designed for budget-constrained customers. The scanner combines high-performance imaging and low capital cost through a sub-$1 million price tag, lower operating costs, and compact siting. The same basic platform drives both the Achieva SE and the high-end Achieva 1.5T A-Series, but the new product is repackaged without the more advanced clinical capabilities of the A-Series. Power-saving features reduce energy consumption -- and energy costs -- by up to 50%, according to Philips.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
New Interventional Radiology Research Shows Merits of Genicular Artery Embolization for Knee OA
December 3rd 2024In a cohort of over 160 patients with knee osteoarthritis (OA), including grade 4 in nearly half of the cases, genicular artery embolization led to an 87 percent improvement in the quality of life index, according to research presented at the